A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

(2013) David H Adams et al.   BMC Psychiatry

Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction

(2012) M Ayalew et al.   MOLECULAR PSYCHIATRY

Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology

(2012) J M Stone et al.   MOLECULAR PSYCHIATRY

P.1.a.012 Confirmation of association between genetic markers in 5HTR2A and response to mGLU2/3 agonist LY2140023 monohydrate in schizophrenia

(2011) L. Nisenbaum et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

(2011) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Translating Glutamate: From Pathophysiology to Treatment

(2011) D. C. Javitt et al.   Science Translational Medicine

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia

(2010) W Liu et al.   PHARMACOGENOMICS JOURNAL

Glutamatergic (N-Methyl-D-aspartate Receptor) Hypofrontality in Schizophrenia: Too Little Juice or a Miswired Brain?

(2009) G. J. Marek et al.   MOLECULAR PHARMACOLOGY

What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

(2008) A. S. Kemp et al.   SCHIZOPHRENIA BULLETIN

A graphical approach to sequentially rejective multiple test procedures

(2008) Frank Bretz et al.   STATISTICS IN MEDICINE